Randomized placebo-controlled trial of sodium valproate in progressive supranuclear palsy

Laurène Leclair-Visonneau [a,b,c,1], Tiphaine Rouaud [a,b,1], Bérangère Debilly [d], Franck Durif [d], Jean-Luc Houeto [e], Alexandre Kreisler [f], Luc Defebvre [f], Estelle Lamy [a,b], Christelle Volteau [g], Jean-Michel Nguyen [g], Séverine Le Dily [a], Philippe Damier [a,b], Claire Boutoleau-Bretonnière [a,b], Pascal Lejeune [h], Pascal Derkinderen [a,b,*]

[a] Inserm, CIC-04, Nantes F-44093, France
[b] CHU Nantes, Department of Neurology, Nantes F-44093, France
[c] CHU Nantes, Department of Physiology, Nantes F-44093, France
[d] CHU Clermont-Ferrand, Department of Neurology, Clermont-Ferrand F-63001, France
[e] CHU Poitiers, Department of Neurology, Poitiers F-86000, France
[f] CHU Lille, Department of Neurology, Lille F-59000, France
[g] CHU Nantes, Pôle d'Information Médicale, Évaluation et Santé Publique (PIMESP), Nantes F-44093, France
[h] CHD La Roche Sur Yon, Department of Neurology, La Roche Sur Yon, F-85000, France

ABSTRACT

Objectives: Results from preclinical studies suggest that inhibition of glycogen synthase kinase (GSK-3) is a therapeutic option for tauopathies. The aim of the present study was therefore to determine the effects of sodium valproate (VPA), a GSK-3 inhibitor, on disease progression in progressive supranuclear palsy (PSP).
Patients and methods: We performed a double-blind, randomized, placebo-controlled trial, in 28 PSP patients who received VPA (1500 mg/day) or matching placebo for 24 months. The primary endpoint was the change from baseline in Progressive Supranuclear Palsy Rating Scale (PSPRS) at 12 and 24 months. Secondary endpoints evaluated the effects of VPA on cognitive and behavioral status (MMSE, Mattis Dementia Rating Scale, Wisconsin Card Sorting, Gröber and Buschke and Oral Denomination 80 tests), tolerability of treatment, and patient compliance.
Results: There were no baseline differences between active treatment and placebo groups in age and clinical rating scores. PSPRS score at 12 months was significantly higher in the VPA than in the placebo group (60.8 ± 20 versus 46.9 ± 18.6 respectively, $p = 0.01$), but was similar between the two groups at 24 months. No significant differences were observed between VPA and placebo groups for the secondary endpoints.
Conclusion: Our results suggest that VPA is not effective as a disease-modifying agent in PSP.

© 2016 Elsevier B.V. All rights reserved.

1. Introduction

Progressive supranuclear palsy (PSP) is an adult-onset neurodegenerative disease, characterized by postural instability, vertical supranuclear gaze palsy, dysarthria, dysphagia, frontal cognitive disturbances and levodopa-unresponsive parkinsonism [1]. The median time from disease onset to death is 5.9 years [2]. No effective symptomatic, disease-modifying or neuroprotective therapy is currently available. Neuropathologically, PSP belongs to the family of tauopathies and is therefore characterized by a widespread neuronal cell loss associated with an abnormal accumulation of intracellular microtubule-associated protein tau in specific basal ganglia and brainstem areas [3].

Under physiological conditions, unphosphorylated tau is soluble and binds reversibly to microtubules [4]. In PSP, tau is hyperphosphorylated by kinases at several serine or threonine residues [5]. Phosphorylated tau loses its affinity for microtubules and becomes resistant to proteolysis, resulting in the formation of cytotoxic tau-aggregates [6]. Two serine/threonine protein kinases, glyco-

gen synthase kinase (GSK-3) and cyclin-dependant kinase-5 are critically involved in abnormal tau phosphorylation [7,8]. GSK-3 is involved in the formation of oligomeric tau fibrils *in vitro* [9] and associated with tau hyperphosphorylation and tangle formation in transgenic models [10,11]. It co-localizes with filamentous tau in transgenic mice [10] and with neurofibrillary tangles in the brain of patients with Alzheimer's disease or PSP [12]. These data suggest that GSK-3 inhibition might constitute a relevant strategy to tackle PSP progression [6]. Sodium valproate (VPA) has been demonstrated to inhibit the activity of both GSK-3 isoforms at clinically achievable concentrations [13]. We therefore undertook a prospective, randomized, double-blind, placebo-controlled trial to assess the safety and efficacy of VPA in slowing the rate of progression of the clinical features of PSP.

2. Patients and methods

2.1. Standard protocol approvals, registration, and patient consents

The study was conducted over a 24-month period (ClinicalTrials.gov identifier: NCT00385710) from December 2006 to July 2008 at 4 centers in France. It complied with the International Conference on Harmonization Good Clinical Practice guidelines, was approved by Ethics Committees/Institutional Review Boards of the coordinating center and conducted according to International standards of Good Clinical Practice (ICH guidelines and the Helsinki Declaration). Participants provided written informed consent before participation.

2.2. Patients

Eligible patients were men and women aged 45–75 years old with possible or probable PSP according to the NINDS-Society for Progressive Supranuclear Palsy [SPSP] diagnostic criteria [14]. Inclusion criteria also included Mini-Mental Status Examination (MMSE) score above 22, PSPRS score under 40, menopause status or contraception and negative β-HCG for women. Exclusion criteria were NINDS-SPSP exclusion criteria, positive syphilis serology test, personal or familial history of severe hepatitis, personal history of allergy to valproate, divalproate, valpromid or sodium valproate excipient, personal history of porphyry, unstable central nervous system medication for the past 3 months, unstable dopaminergic treatment for the past month as well as prohibited associated treatment (mefloquin, St.-John's-wort, anticonvulsivant, neuroleptic except clozapine, medication metabolizing to valproate such as valproate, valpromid).

2.3. Study design

This study was designed as a randomized, double-blind placebo-controlled, parallel-group, multicentric phase II trial, assessing the efficacy and safety of VPA at a single dose (1500 mg per day). Randomization was balanced by center. The 1:1 randomization sequence was produced by the statistics department from Nantes University Hospital (Nantes, France). The randomization list was sent to an independent contract research organization (LC2, Lentilly, France), which prepared and distributed identical capsules of VPA and placebo. Assignment was masked from the patients, study staff, investigators, and data analysts.

After randomization, VPA or matching placebo was administered following a weekly dose titration, beginning at one tablet (500 mg in VPA group) per day, then b.i.d (1000 mg in sodium valproate group), and up to t.i.d (1500 mg in VPA group) the third week, a dose that was maintained during the entire study duration. Patients were contacted by phone 15 days after treatment initiation

to check for treatment tolerability and the occurrence of potential adverse effects. Treatments were delivered at inclusion, at 1 month, 3 months, and then every 3 months until the end of the study. After a 24-month period, treatment was gradually tapered to a stop following a one tablet (500 mg in VPA group) weekly dose decrease.

2.4. Evaluation

MMSE was completed during selection visit. Demographic data, initial symptoms, date of onset, disease duration, diagnostic classification according NINDS-SPSP criteria, personal medical history, actual and past month treatment, general and neurological clinical examination including PSPRS score, were completed during inclusion visit. Biological analysis were done at inclusion, including full blood count, electrolytes, kidney and liver functions, TPHA-VDRL syphilis serology, and β-HCG level.

The primary endpoint evaluated the effect of VPA on disease clinical progression as assessed by the PSPRS score at 12 and 24 months. Secondary endpoints evaluated the effects of VPA on cognitive and behavioral status, the tolerability of the treatment, and patient compliance to treatment.

The PSPRS score was assessed at inclusion, at 1 month, at 3 month, and then every 3 months until 24 months after inclusion and after treatment discontinuation at 25 months [15]. Neuropsychological and behavioral statuses were evaluated at inclusion, 12 months and 24 months after inclusion. Neuropsychological tests included a global cognitive evaluation (MMSE, Mattis Dementia Rating Scale MDRS), an evaluation of executive functions (Wisconsin Card Sorting Test, verbal fluency), verbal episodic memory (Gröber and Buschke test) and language (Oral Denomination 80 test), behavioral impairment was rated by Neuropsychiatric Inventory (NPI).

Clinical and biological tolerability was evaluated at each following visit. Clinical examination comprised weight, blood pressure and pulse rate. Biological tests consisted in full blood count, electrolytes, and kidney and liver analyses. Most frequent expected adverse events under treatment were gastrointestinal symptoms, weight gain, dizziness or sleepiness, tremor and hair loss.

2.5. Statistical analyses

Continuous data were expressed as the mean $\pm$ standard deviation and categorical data were expressed as numbers and percentage. PSPRS score, MDRS score, NPI score at 12 months and 24 months and weight at 24 months were compared between VPA and placebo group with rank analysis of covariance after adjusting for baseline value. Number of adverse events, number of severe adverse events and observance were compared between groups with Wilcoxon tests. Overall survivals were compared between the two groups using Log-Rank test. SAS software version 9.1 (SAS Institute Inc, Cary, North Carolina). For all statistical tests p < 0.05 was deemed significant.

3. Results

3.1. Study population

Thirty-six patients were assessed for eligibility (Fig. 1). Eight were not eligible. Twenty-eight met the inclusion and exclusion criteria and were therefore randomized. Fourteen were assigned to receive placebo and 14 to VPA. One patient allocated to VPA discontinued the study before follow-up, because of early interruption of treatment. Twenty-seven patients entered the study. Baseline

Fig. 1. Study flow chart.

Table 1
Population characteristics at baseline.

	Sodium valproate (N = 13)	Placebo (N = 14)
Sex (male)	6 (46%)	8 (57%)
Age (years)	66,1 (6,1)	67,1 (7,2)
Disease duration (years)	3,0 (1,6)	3,6 (2,4)
Weight (kg)	69,9 (16,9)	79,1 (18,2)
Levodopa use	12 (92)	10 (71)
Mean daily dose of Levodopa (mg)	379 (202)	395 (315)
PSPRS score	33,4 (4,3)	32,1 (7,7)
history	8,2 (1,7)	6,9 (2,4)
mentation	3,0 (2,0)	2,9 (1,7)
bulbar	1,9 (0,8)	2,7 (1,2)
ocular motor	7,5 (2,3)	7,6 (3,4)
limb motor	4,8 (2,4)	4,7 (2,3)
gait and midline	8,1 (3)	7,4 (2,3)
MMSE score	26,4 (1,7)	27,3 (2,4)
Neuropsychological assessment		
FAB	9,8 (2,9)	11,0 (3,5)
MDRS	114,7 (13,3)	118,2 (14,3)
WCST (criteria)	2,9 (2,0)	3,0 (1,3)
WCST (perseveration)	9,2 (7,1)	13,2 (7,3)
Gröber et Buschke test	42,8 (7,0)	42,9 (12,0)
verbal fluency test (letter)	7,3 (3,4)	9,4 (7,1)
verbal fluency test (animals)	13,0 (6,4)	14,9 (7,7)
oral denomination 80 test	74,2 (4,7)	75,3 (4,5)
Neuropsychiatric Inventory	24,8 (13,7)	19,9 (17,5)

Data are means (SD) or numbers (%). PSPRS = progressive supranuclear palsy rating scale, MMSE = mini-mental status examination, FAB = frontal assessment battery, MDRS = Mattis dementia rating scale, WCST = Wisconsin card sorting test

demographics, history, cognitive and behavioral assessments were not different between the VPA and placebo groups (Table 1).

3.2. Clinical outcome

Six patients in the VPA and 13 patients in the placebo group completed the study. During follow-up, 8 patients discontinued intervention in the VPA group owing to serious adverse effects in 4 cases (3 deaths), adverse effects in 2 cases, impossibility to administer treatment in one case and lost of follow-up in one case. One patient discontinued intervention in the placebo group (death) (Fig. 1). Mean treatment duration was 18.3 months. It was shorter in the VPA than in the placebo group (14.6 ± 9.2 versus 22 ± 5.3 months, respectively; $p = 0.02$).

PSPRS score at 12 months was significantly higher in the VPA group than in the placebo group (60.8 ± 20 versus 46.9 ± 18.6 respectively, $p = 0.01$) but no difference was observed between the two groups at 24 months (67.6 ± 14.5 in the VPA group versus 59.4 ± 16.1 in the placebo group, $p = 0.10$). PSPRS score evolution is shown in Fig. 2. A trend toward a worsening in gait and midline PSPRS subscores was observed at 12 months in the VPA as compared to placebo group but it did not reach significance (Table 2).

Because of general impairment, complete neuropsychological assessment was performed in only 11 patients at 12 months and 7 at 24 months. MDRS was completed in 19 patients at 12 months (8 in the VPA and 11 in the placebo group) and in 17 patients at 24 months (6 in the VPA and 11 in the placebo group). There were no differences between the two groups regarding MDRS scores either at 12 or 24 months (93.2 ± 19 and 87.5 ± 19.7 in the VPA group versus 106.4 ± 25.1 and 102.9 ± 22.9 in the placebo group, respectively; $p = 0.27$ at 12 months and $p = 0.18$ at 24 months). NPI was listed in 18 patients at 12 months (7 in the VPA and 11 in the placebo group) and in 18 patients at 24 months (6 in the VPA

Fig. 2. PSPRS score evaluations at baseline, over the 24-month treatment period and one month after discontinuation (25 months). Solid line: VPA-treated group; broken line: placebo group.

Table 2
PSPRS subscores at 12 and 24 months.

	Sodium valproate (N = 13)	Placebo (N = 14)	p
PRSPRS at 12 months	60.8 (20)	46.9 (18.6)	0.01
history	10.7 (4.6)	8.1 (3.2)	0.41
mentation	4.6 (3.4)	3.1 (1.7)	0.46
bulbar	4.2 (2.3)	3.5 (1.7)	0.37
ocular motor	10.6 (3.3).	9.8 (3.5)	0.26
limb motor	7.6 (2.9)	6.1 (2.3)	0.18
gait and midline	15.3 (4.4).	11.1 (5.9)	0.07
PRSPRS at 24 months	**67.6 (14.5)**	**59.4 (16.1)**	**0.1**
history	13 (3.4)	11.1 (2.9)	0.45
mentation	6.7 (2.8)	6.1 (3.6)	0.5
bulbar	4.3 (2.0)	4.5 (1.7)	0.72
ocular motor	12.4 (1.7)	12.1 (3.1)	0.9
limb motor	9.1 (3.0)	7.7 (2.8)	0.2
gait and midline	17.7 (1.6)	15.7 (4.1)	0.38

Data are means (SD).
PSPRS = progressive supranuclear palsy rating scale.

group and 12 in the placebo group). No difference in NPI score was observed between the two groups at 12 months (24.6 ± 12 in the VPA group versus 18.6 ± 14.2 in the placebo group, p = 0.24) and at 24 months (29.8 ± 31.7 in the VPA group versus 18.8 ± 11.8 in the placebo group, p = 0.08).

In each group, one patient underwent nutritional assistance by gastrostomy. There was no significant difference in weight evolution between the two groups at 24 months (0.2 ± 11.8 gain in the VPA group and 7.5 kg ± 8.5 loss in the placebo group, p = 0.18).

3.3. Tolerability, security and observance

Tolerability monitoring showed an average of 4.4 ± 2.7 adverse events per patient treated with VPA and 5.3 ± 3.2 with placebo (p = 0.48). The most frequent adverse effects were sleepiness or fatigue (5 in VPA, 5 in placebo group), gastrointestinal disorders (5 in VPA, 1 in placebo group), balance or gait disorders (4 in VPA, 5 in placebo group) and hallucinations (2 in VPA group). There were no significant biological abnormalities. Severe adverse effects were observed in 9 VPA- and 6 placebo-treated patients: severe infection (5 in VPA, 1 in placebo group), worsening in gait disorders (3 in VPA, 2 in placebo group), breast cancer (1 in placebo). Three patients died during the follow-up in the VPA group (2 from septicemia, one from aspiration pneumonia) and one from septicemia

in placebo group. Survival was similar between the two groups (p = 0.24). Mean observance was not different between the two groups (88.5% in VPA group and 96.8% in placebo group (p = 0.08)).

4. Discussion

Our results show that VPA-up to 1500 mg/day for 24 months-is not effective as a disease-modifying agent in PSP, either on motor, cognitive or behavioral symptoms.

VPA was used in the present survey because preclinical studies demonstrated that it inhibits GSK-3, which is involved in abnormal tau phosphorylation/aggregation and thus in the pathogenesis of tauopathies [16,17]. Two recent, negative, 1-year, multicenter trial of the GSK3 inhibitors tideglusib and davunetide also used PSPRS as a primary outcome measure and identified a similar rate of decline [18,19].

Aside from human studies, the effects of lithium, another inhibitor of GSK-3, were evaluated in transgenic mice overexpressing mutant human tau [11]. Mice treated with lithium displayed reduced levels of aggregated insoluble tau along with a less severe axonal degeneration as compared to placebo-treated animals. Remarkably, lithium-treated mice showed less degeneration if administration was started during early stages of pathology progression, suggesting that tauopathy process become more resistant to the neuroprotective effects of the treatment with disease progression [11]. This could explain the lack of beneficial effects of VPA as well as other GSK3 inhibitors in clinical studies as patients already exhibited full-blown PSP symptoms when they received the putative neuroprotective therapy.

It is logical to assume that a neuroprotective agent should be started in the earliest phase of neurodegenerative disorder in order to demonstrate efficacy. This explains why we have restricted our recruitment to patients with a PSPRS score at baseline under 40, which reflects moderate evolution [15]. Even so, it is likely that the neurodegenerative process in our patients started several years before the diagnosis of possible or probable PSP was made. Autopsy surveys have indeed demonstrated that abnormal tau aggregates occur within neurons of the locus coeruleus of non-demented individuals under 40 [20]. Given that the locus coeruleus is constantly affected by pathology during PSP [21], one could postulate that these individuals may represent very early stage of tauopathies and especially PSP. Further reinforcing this

assumption is the recent description by Beach and collaborators of 5 patients with histopathological findings suggestive of PSP, without clinical PSP, dementia or parkinsonism during life [22]. These incidental neuropathological PSP findings may represent the pre-symptomatic stage for PSP, likewise incidental Lewy bodies disease for Parkinson's disease [23].

The worsening in PSPRS score observed in VPA-treated patients disappeared when the treatment was withdrawn, strongly suggesting that it was due to poor tolerability rather than to a permanent neurodamaging effect. This poor tolerability may account for the higher dropout rate and the shorter duration of treatment in the VPA-treated group as compared to control subjects. Poor tolerability of VPA has been previously reported in a controlled study that was primarily designed to determine whether it could delay or prevent emergence of agitation or psychosis in Alzheimer's disease [24]. In this survey, VPA treatment had no beneficial effects on agitation or psychotic symptoms and was moreover associated with higher rates of somnolence, gait disturbance, tremor and weakness [24]. Taken together, these results and the ones from our study strongly suggest that patients with neurodegenerative disorders and especially tauopathies are more sensitive to VPA. Whether this poor tolerability results from the occurrence of a VPA-induced mild reversible encephalopathy on a damaged atrophied brain remains to be determined [25].

Despite several limitations to our study such as the small population size and the use of a single escalating dose of VPA, our findings suggest that VPA is not effective as a disease-modifying treatment in PSP. It also underscores the importance of early detection of PSP, as already proposed for other neurodegenerative disorders [26], in order to provide earlier interventional therapies.

Acknowledgments

References

[1] J.C. Steele, J.C. Richardson, J. Olszewski, Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia, Arch. Neurol. 10 (1964) 333–359.

[2] I. Litvan, C.A. Mangone, A. McKee, M. Verny, A. Parsa, K. Jellinger, et al., Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study, J. Neurol. Neurosurg. Psychiatry 60 (1996) 615–620.

[3] J.J. Hauw, S.E. Daniel, D. Dickson, D.S. Horoupian, K. Jellinger, P.L. Lantos, et al., Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy), Neurology 44 (1994) 2015–2019.

[4] D.P. Hanger, D.H.W. Lau, E.C. Phillips, M.K. Bondulich, T. Guo, B.W. Woodward, et al., Intracellular and extracellular roles for tau in neurodegenerative disease, J. Alzheimers Dis. 40 (Suppl. 1) (2014) S37–45.

[5] G.M. Gibb, R. de Silva, T. Revesz, A.J. Lees, B.H. Anderton, D.P. Hanger, Differential involvement and heterogeneous phosphorylation of tau isoforms in progressive supranuclear palsy, Brain Res. 121 (2004) 95–101.

[6] D.P. Hanger, B.H. Anderton, W. Noble, Tau phosphorylation: the therapeutic challenge for neurodegenerative disease, Trends Mol. Med. 15 (2009) 112–119.

[7] W. Noble, V. Olm, K. Takata, E. Casey, O. Mary, J. Meyerson, et al., Cdk5 is a key factor in tau aggregation and tangle formation in vivo, Neuron 38 (2003) 555–565.

[8] S.F. Mulot, K. Hughes, J.R. Woodgett, B.H. Anderton, D.P. Hanger, PHF-tau from Alzheimer's brain comprises four species on SDS-PAGE which can be mimicked by in vitro phosphorylation of human brain tau by glycogen synthase kinase-3 beta, FEBS Lett. 349 (1994) 359–364.

[9] S. Sato, Y. Tatebayashi, T. Akagi, D.-H. Chui, M. Murayama, T. Miyasaka, et al., Aberrant tau phosphorylation by glycogen synthase kinase-3beta and JNK3 induces oligomeric tau fibrils in COS-7 cells, J. Biol. Chem. 277 (2002) 42060–42065.

[10] T. Ishizawa, N. Sahara, K. Ishiguro, J. Kersh, E. McGowan, J. Lewis, et al., Co-localization of glycogen synthase kinase-3 with neurofibrillary tangles and granulovacuolar degeneration in transgenic mice, Am. J. Pathol. 163 (2003) 1057–1067.

[11] W. Noble, E. Planel, C. Zehr, V. Olm, J. Meyerson, F. Suleman, et al., Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo, Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 6990–6995.

[12] I. Ferrer, M. Barrachina, B. Puig, Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimers disease, Picks disease, progressive supranuclear palsy and corticobasal degeneration, Acta Neuropathol. 104 (2002) 583–591.

[13] G. Chen, W.Z. Zeng, P.X. Yuan, L.D. Huang, Y.M. Jiang, Z.H. Zhao, et al., The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS, J. Neurochem. 72 (1999) 879–882.

[14] I. Litvan, Y. Agid, J. Jankovic, C. Goetz, J.P. Brandel, E.C. Lai, et al., Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome), Neurology 46 (1996) 922–930.

[15] L.I. Golbe, P.A. Ohman-Strickland, A clinical rating scale for progressive supranuclear palsy, Brain 130 (2007) 1552–1565.

[16] Y. Tatebayashi, N. Haque, Y.-C. Tung, K. Iqbal, I. Grundke-Iqbal, Role of tau phosphorylation by glycogen synthase kinase-3beta in the regulation of organelle transport, J. Cell Sci. 117 (2004) 1653–1663.

[17] H. Dou, K. Birusingh, J. Faraci, S. Gorantla, L.Y. Poluektova, S.B. Maggirwar, et al., Neuroprotective activities of sodium valproate in a murine model of human immunodeficiency virus-1 encephalitis, J. Neurosci. 23 (2003) 9162–9170.

[18] E. Tolosa, I. Litvan, G.U. Höglinger, D. Burn, A. Lees, M.V. Andrés, et al., A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy, Mov. Disord. 29 (2014) 470–478.

[19] A.L. Boxer, A.E. Lang, M. Grossman, D.S. Knopman, B.L. Miller, L.S. Schneider, et al., Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial, Lancet Neurol. 13 (2014) 676–685.

[20] R.W. Shin, T. Kitamoto, J. Tateishi, Modified tau is present in younger nondemented persons: a study of subcortical nuclei in Alzheimer's disease and progressive supranuclear palsy, Acta Neuropathol. 81 (1991) 517–523.

[21] D.W. Dickson, R. Rademakers, M.L. Hutton, Progressive supranuclear palsy: pathology and genetics, Brain Pathol. 17 (2007) 74–82.

[22] V.G.H. Evidente, C.H. Adler, M.N. Sabbagh, D.J. Connor, J.G. Hentz, J.N. Caviness, et al., Neuropathological findings of PSP in the elderly without clinical PSP: possible incidental PSP? Parkinsonism Relat. Dis. 17 (2011) 365–371.

[23] H. Braak, K. Del Tredici, U. Rub, R.A. de Vos, E.N. Jansen Steur, E. Braak, Staging of brain pathology related to sporadic Parkinson's disease, Neurobiol. Aging 24 (2003) 197–211.

[24] A.S. Fleisher, D. Truran, J.T. Mai, J.B.S. Langbaum, P.S. Aisen, J.L. Cummings, et al., Chronic divalproex sodium use and brain atrophy in Alzheimer disease, Neurology 77 (2011) 1263–1271.

[25] N. Segura-Bruna, A. Rodriguez-Campello, V. Puente, J. Roquer, Valproate-induced hyperammonemic encephalopathy, Acta Neurol. Scand. 114 (2006) 1–7.

[26] P.A. Agarwal, A.J. Stoessl, Biomarkers for trials of neuroprotection in Parkinson's disease, Mov. Disord. 28 (2013) 71–85.